Abstract:

The commonly used treatment method for intrauterine adhesions(IUA) is hysteroscopic transcervical resection of adhesion, but the postoperative recurrence rate is high, and the risk of postoperative endometrial injury is also high. The curative effect of drugs, including oral estrogen, tamoxifen, aspirin, subcutaneous injection of GnRH agonists, intrauterine injection of the low dose of human chorionic gonadotropin, etc., is unstable, while the treatment cycle is long. In recent years, the development of cell therapy and regenerative medicine has provided a new research direction for the treatment of IUA. Good therapeutic effects of intrauterine perfusion or intravenous infusion of stem cell suspension, intrauterine infusion of platelet-rich plasma, growth factors and related biological materials have been reported. A variety of new adjuvant therapy measures developed on the basis of cell therapy have been gradually applied in the practice of IUA treatment, as the ideal methods to prevent readhesion. Combined with gels, scaffolds and other biological materials, these adjuvant measures also provide a new treatment idea for the refractory IUA.

Key words: Stem cells, Platelet-rich plasma, Tissue engineering, Hysteroscopy, Regenerative medicine, Intrauterine adhesions